# TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC

> **NCT05332496** · — · COMPLETED · sponsor: **Zhongda Hospital** · enrollment: 941 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT05332496
- **Lead sponsor:** Zhongda Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-28
- **Primary completion:** 2023-07-30
- **Final completion:** 2025-09-14
- **Target enrollment:** 941 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05332496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05332496, "TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05332496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*